KR102069125B1 - Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract - Google Patents

Abstract

The present invention relates to a composition for preventing and treating liver damage, and more particularly, to a pharmaceutical composition for preventing and treating liver damage, including turmeric extract, which can prevent and treat liver damage by improving liver cell protection effect according to liver toxicity. It is about.

Description

Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract}

The present invention relates to a composition for preventing and treating liver damage, and more particularly, to improve the liver cell protective effect according to liver toxicity, turmeric extract, fractions thereof and / or components separated therefrom which can prevent and treat liver damage. It relates to a pharmaceutical composition for preventing and treating liver damage.

The liver is the most active organ of human body in vivo metabolism is also the largest organ of the human body. The liver is located between the digestive system and the systemic circulatory system and serves to protect the whole body from in vitro substances from outside. The liver is also a very important organ responsible for various metabolism, detoxification, degradation, synthesis and secretion.

More specifically, the liver has a function of managing energy metabolism, so that all the nutrients absorbed from the food are metabolized into substances capable of producing energy in the liver, which are supplied or stored throughout the body, and about 2,000 kinds of enzymes, albumin, and coagulation Serum proteins, bile acids, phospholipids, and fats such as cholesterol are synthesized, stored and distributed in the liver. The liver also plays an important role in maintaining our lives because it has the ability to excrete various metabolites into the duodenum through the bile ducts and immune function. In addition, since the liver detoxifies drugs, alcohol, toxic substances and the like as a detoxifying and degrading function, hepatocytes are susceptible to damage and thus drug, toxic, alcoholic liver diseases, and the like can frequently occur. In addition, since the ex vivo substance enters the liver, the liver has a higher risk of being exposed to many toxic substances in addition to nutrients, which is more likely to be damaged.

Among the causes of liver disease, liver damage caused by drugs is the top. In particular, acetaminophen (AAP) is an analgesic and anti-inflammatory drug known as Tylenol, which is the most commonly used in the world, but is reported to cause acute liver damage (liver necrosis, neurotoxins, liver cirrhosis, etc.) in high doses. have.

Accordingly, there is a need for the development of materials capable of preventing or treating liver damage caused by chemicals, particularly drugs such as acetaminophen.

On the other hand, turmeric is a kind of Zingiberaceae and its scientific name is Curcuma longa . It is used as a spice in tropical regions of Southeast Asia, and has been widely used as a traditional medicine due to its strong antioxidant and anti-inflammatory properties. Curcuma longa has antifungal activity (Apisariyakul Amphawan et al., 1995, Antifungal activity of turmeric oil extracted from Curcuma longa, Journal of Ethnopharmacology, Vol. 49, No. 3, pp.163 ~ 169), anti-inflammatory, anti-HIV Biological activities (CAC Araujo et al., 2001, Biological activities of Curcuma longa L., MEMORIAS DO INSTITUTO OSWALDO CRUZ, pp. 723-728) have been reported. There have been no studies showing that turmeric extract is effective in preventing and treating liver damage caused by liver toxicity.

The present invention has been made in view of the above, it is possible to prevent and treat liver damage by improving the hepatocellular protective effect according to liver toxicity, hepatic damage prevention and treatment pharmaceutical composition comprising turmeric extract and functional ingredients or It is an object to provide a food composition for preventing and improving liver damage.

In order to solve the above problems, the present invention provides a pharmaceutical composition for the prevention and treatment of liver damage, comprising turmeric ( Curcuma longa ) extract or a fraction thereof comprising the compound represented by the following formula (1) as an active ingredient.

[Formula 1]

According to one embodiment of the invention, the extract may be extracted through water, C1 ~ C4 alcohol or a mixed solvent thereof.

In addition, the fraction may be obtained by fractionating the turmeric extract through a solvent roll containing n-butanol.

In addition, the liver damage may be due to acetaminophen (Acetaminophen) drug.

In addition, the present invention provides a pharmaceutical composition for preventing and treating liver damage, comprising a compound represented by the following formula (1) or a salt thereof as an active ingredient.

[Formula 1]

According to one embodiment of the present invention, the compound represented by Chemical Formula 1 may be derived from Curcuma longa .

In another aspect, the present invention provides a food composition for preventing and improving liver damage, comprising a turmeric ( Curcuma longa ) extract or a fraction thereof as an active ingredient comprising a compound represented by the formula (1).

[Formula 1]

In another aspect, the present invention provides a food composition for preventing and improving liver damage comprising a compound represented by the following formula (1) or a salt thereof as an active ingredient.

[Formula 1]

According to one embodiment of the present invention, the compound represented by Chemical Formula 1 may be derived from Curcuma longa .

Hereinafter, terms used in the present invention will be described.

As used herein, the term "prevention" in the present invention means any action that inhibits liver injury or delays the onset by administration of the composition.

As used herein, the term "treatment" means any action that improves or advantageously changes the symptoms caused by liver damage by administration of the composition.

According to the composition according to the present invention, it is possible to significantly prevent, treat or improve liver damage by protecting the liver cells from liver damage caused by liver toxicity, in particular, liver toxicity caused by the drug, and thus preventing, treating and improving liver damage. It can be widely applied as a functional food.

Figure 1 is a graph of liver cell survival rate according to one embodiment and a comparative example of the present invention treated in human liver cell line induced liver damage by acetaminophen.
Figure 2 is a graph of the AST activity of liver cells according to one embodiment of the present invention and a comparative example treated with human liver cell line induced liver damage by acetaminophen.
Figure 3 is a graph of the LDH concentration of liver cells according to one embodiment of the present invention and a comparative example treated to human liver cell line induced liver damage by acetaminophen.

Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily practice. As those skilled in the art would realize, the described embodiments may be modified in various different ways, all without departing from the spirit or scope of the present invention.

First, the pharmaceutical composition for preventing and treating liver damage according to an embodiment of the present invention includes Curcuma longa extract or a fraction thereof including the compound represented by Formula 1 as an active ingredient.

[Formula 1]

First, turmeric extract will be described.

The turmeric (Cu rcuma longa) to be extracted may be purchased and used commercially, or may be one collected or grown in nature. In addition, the turmeric may use any one or more parts of the root, stem, and leaves, preferably root. In this case, the turmeric is not limited to whether the object is dried or pulverized during extraction, but preferably dried and pulverized may be used.

The turmeric extract may be extracted using a conventional extraction method in the art, and may be, for example, ultrasonic extraction, filtration and reflux extraction. In one specific embodiment, the turmeric pulverized pulverized turmeric from which the foreign matter is removed by washing and drying may be extracted through water, C1 ~ C4 alcohol or an extraction solvent which is a mixed solvent thereof. More preferably, the extraction solvent may be extracted using ethanol or ethanol aqueous solution. At this time, the extract may be extracted for 15 to 36 hours at a temperature condition of 20 ~ 30 ℃. In addition, after extracting once, the extract is filtered and the remaining extract is extracted again two to four times under the same conditions to obtain an extract.

The obtained extract may be included in the composition as it is or may be concentrated under reduced pressure. At this time, the decompression concentration can be carried out under conditions conventionally used in the art, and thus the detailed description thereof will be omitted.

Next, the fraction of turmeric extract will be described.

The fraction may be a fraction of the turmeric extract obtained by the above-mentioned method using water, ethyl acetate and any one or more fraction solvents of n-butanol using a conventional fractionation method in the art, preferably preventing liver damage , N-butanol fraction for turmeric ethanol extract in terms of the content of the therapeutically active ingredient.

An example of obtaining the fractions will be described. The turmeric ethanol extract is partitioned and extracted through water and ethyl acetate, and then the aqueous layer is partitioned and extracted with n-butanol, and each layer is concentrated under reduced pressure to obtain an ethyl acetate fraction, n-butanol. Fractions and water fractions can be obtained.

According to a preferred embodiment of the present invention, the extract and the fraction comprises a compound represented by the following formula (1), through which can express a significant effect on the prevention and treatment of liver damage.

[Formula 1]

Specifically, the compound represented by Chemical Formula 1 has an effect of inhibiting liver toxicity induced by acetaminophen treatment, thereby improving cell survival rate of human liver cancer cell line (HepG2), and in particular, even when treated at a lower concentration than the positive control silymarin It can be seen that the protective effect is more excellent.

In addition, as can be seen through Figure 2, it can be seen that the AST activity level increased by acetaminophen treatment is significantly reduced through the treatment of the compound represented by the formula (1). In addition, it can be seen that more effective in reducing the AST activity level than silymarin treated at a higher concentration.

In addition, as can be seen from Figure 3, when the hepatocytes are killed by damage is released by the LDH (Lactate dehydrogenase) enzyme present in the hepatocytes out of the cell increases the concentration, the increased LDH concentration by acetaminophen treatment to Formula 1 It can be seen that significantly reduced through the treatment of the compound is displayed, through which the killing inhibitory effect on the hepatocytes damaged by the drug can be seen. In addition, it can be seen that more effective in reducing the LDH concentration than the higher concentration of silymarin treated.

As described above, the compound represented by Chemical Formula 1 may be referred to as an active ingredient included in a turmeric extract or a fraction thereof to prevent and treat liver damage. Separation and purification through silica gel column chromatography and Sephadex LH-20 column chromatography, can be carried out from one to several times until a single compound is purified, concentrated as necessary, Recrystallization can be carried out.

As an example, the obtained n-butanol fraction may be fractionated using silica gel column chromatography (inner diameter 10 × 20 cm, elution solvents CHCl _3, MeOH and H ₂ O by volume ratio 10-20: 2-5: 1). After confirming each aliquot by thin layer chromatography (TLC), silica gel column chromatography (inner diameter 3 × 20 cm, elution solvent CHCl _3, MeOH and H ₂ O) was again performed on each of the five fractions obtained. Volume fraction of 5 to 15: 2 to 5: 1) to obtain a re-fraction for each fraction. Thereafter, octadecyl silica gel column chromatography (ODS cc), an inner diameter of 2 × 10 cm, and a volume ratio of MeOH and H ₂ O were performed on each of the redistributions. Can be obtained, and the compounds represented by the above-described formula (1) can be obtained among these reclaimed. In this case, the yield of the compound represented by Formula 1 may be about 10 mg of the compound represented by Formula 1 based on 50 g of n-butanol fraction.

The compound represented by Chemical Formula 1 separated and purified by the above-described method may be included in the form of a pharmaceutically acceptable salt. As the salts, acid addition salts formed by pharmaceutically acceptable free acid are useful. Acid addition salts include inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid and aliphatic mono and dicarboxylates, phenyl-substituted alkanoates, hydroxy alkanoates and alkanes. Obtained from non-toxic organic acids such as dioates, aromatic acids, aliphatic and aromatic sulfonic acids. Such pharmaceutically nontoxic salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, pyrophosphate chloride, bromide, and iodide. Id, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suverate , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitro benzoate, hydroxybenzoate, meth Oxybenzoate, phthalate, terephthalate, benzenesulfonate, toluenesulfonate, chlorobenzenesul Nate, Xylene Sulfonate, Phenyl Acetate, Phenylpropionate, Phenyl Butyrate, Citrate, Lactate, β-hydroxybutyrate, Glycolate, Maleate, Tartrate, Methanesulfonate, Propanesulfonate, Naphthalene-1- Sulfonates, naphthalene-2-sulfonates or mandelate.

In addition, the acid addition salt is a conventional method, for example, by dissolving the compound represented by the formula (1) in an excess of an aqueous solution of acid, and dichloride is a water miscible organic solvent, such as methanol, ethanol, acetone or acetonitrile Can be prepared by precipitation.

In addition, the compound represented by Formula 1 of the present invention can be used in the form of a pharmaceutically acceptable metal salt using a base. Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is pharmaceutically suitable to prepare sodium, potassium or calcium salt as the metal salt. Corresponding silver salts can also be obtained by reacting alkali or alkaline earth metal salts with a suitable silver salt (eg, silver nitrate).

In addition, the pharmaceutical composition according to one embodiment of the present invention may include a pharmaceutically acceptable carrier. The composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.

When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin. In addition to simple excipients, lubricants such as magnesium stearate, talc and the like are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included. have. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

In addition, the pharmaceutical composition is selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have either formulation.

In addition, the pharmaceutical compositions of the present invention may be administered in a pharmaceutically effective amount. As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the extent of liver damage, the cause of liver damage, age, sex , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently, and other factors well known in the medical field. However, for the desired effect, the pharmaceutical composition according to one embodiment of the present invention is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 100 mg / kg, and the compound represented by the formula (1) The compound represented by 2, or a mixture thereof is preferably administered at 0.0001 to 100 mg / kg, preferably at 0.001 to 10 mg / kg. The compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations. In consideration of all the above factors, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, and can be easily determined by those skilled in the art.

In addition, the pharmaceutical composition according to one embodiment of the present invention may be administered by various methods known in the art, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration Administration, intrapulmonary administration, rectal administration, but is not limited thereto.

In addition, according to another embodiment of the present invention, the pharmaceutical composition for preventing and treating liver damage includes the compound represented by the following formula (1) or a salt thereof as an active ingredient.

[Formula 1]

In this case, preferably, the compound represented by Chemical Formula 1 may be derived from turmeric (Cu rcuma longa) .

On the other hand, the description of the pharmaceutical composition such as the compound represented by the formula (1) or salts thereof is the same as described above and will be omitted below.

The pharmaceutical composition for preventing and treating liver damage according to the present invention described above is effective in preventing and treating liver damage caused by various causes, but can express particularly excellent effect on liver damage caused by acetaminophen drugs.

Next, the present invention includes a food composition for preventing and improving liver damage, including turmeric (Cu rcuma longa) extract or a fraction thereof including the compound represented by Formula 1 as an active ingredient.

That is, turmeric extract or fractions thereof may be added to the food composition for the purpose of preventing and improving liver damage. In addition, the extract and fractions thereof include the compound represented by the above formula (1).

In this case, the extract, fractions may be added as it is or used with other foods or food ingredients, and may be appropriately used according to conventional methods. The mixed amount of the active ingredient can be suitably determined according to the purpose of use (prevention, health or therapeutic treatment). In general, turmeric extract of the present invention or fractions thereof in the manufacture of food or beverage may be added in an amount of 0.01 to 10% by weight, preferably 0.1 to 3% by weight of the raw material composition, but is not limited thereto. It may be added in consideration of the period and the like.

There is no particular limitation on the kind of the food. Examples of foods include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, teas, drinks, alcoholic drinks and vitamin complexes. It includes all of the health food in the usual sense.

In addition, in the case of a health beverage composition, various flavors or natural carbohydrates, etc. may be contained as additional ingredients, as in the usual beverage. The natural carbohydrates described above may be glucose, monosaccharides such as fructose, malsaccharides, disaccharides such as sucrose, and polysaccharides such as dextrin, cyclodextrin, sugar alcohols such as xylitol, sorbitol, erythritol. As the sweetener, natural sweeteners such as tautin and stevia extract, synthetic sweeteners such as saccharin, aspartame, and the like can be used. The ratio of the natural carbohydrate may generally be about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g, per 100 ml of the composition of the present invention, but is not limited thereto.

Also used in many other nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonated drinks It may contain a carbonation agent or the like. The proportion of such additives is not critical but is usually chosen in the range of 0.01 to 0.1% by weight, based on the total composition weight. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. The proportion of such pulp is not critical but is usually selected in the range of 0.01 to 10% by weight, based on the total composition weight. These components can be used independently or in combination.

In addition, the liver composition for preventing and improving liver damage according to an embodiment of the present invention includes a compound represented by the following formula (1) or a salt thereof as an active ingredient.

[Formula 1]

In this case, preferably, the compound represented by Chemical Formula 1 may be derived from turmeric (Cu rcuma longa) .

On the other hand, the description of the food composition such as the compound represented by the formula (1) or salts thereof is the same as described above and will be omitted below.

The above-described composition for preventing and improving liver damage according to the present invention is effective in preventing and improving liver damage caused by various causes, but may exhibit particularly excellent effect on liver damage caused by acetaminophen drug.

Although the present invention will be described in more detail with reference to the following examples, the following examples are not intended to limit the scope of the present invention, which will be construed as to aid the understanding of the present invention.

Example 1

For 5 kg of dried and pulverized turmeric sample, 70% ethanol aqueous solution was extracted as an extraction solvent at 25 ° C. for 24 hours. After the extracted sample was filtered, the remaining sample was extracted two more times in the same manner. The combined filtrates were then concentrated under reduced pressure to obtain an ethanol extract. The ethanol extract obtained was partitioned and extracted with ethyl acetate (3 L × 2 / H ₂ O (3 L), and the H ₂ O layer was extracted with n-BuOH (2.5 L × 2). Concentration gave an ethyl acetate fraction (250 g), an n-butanol fraction (100 g) and a H ₂ O fraction.

50 g of the obtained n-butanol fraction (CUB) was subjected to silica gel column chromatography (inner diameter 10 x 20 cm, elution solvents CHCl _3, MeOH and H ₂ O in a volume ratio of 15: 3: 1), and each aliquot (200). ml) was identified by thin layer chromatography (TLC) to obtain five fractions (CUB-1 to CUB-10). Among them, 300 mg of CUB-10 fractions were subjected to silica gel column chromatography (inner diameter 3 × 20 cm, volume ratio of CHCl _3, MeOH and H ₂ O 9: 3: 1) to give five fractions (CUB-10- 1 ~ CUB-10-5), octadecyl column chromatograph (ODS cc), inner diameter 2 × 10 cm, volume ratio of MeOH and H ₂ O for 50 mg of CUB-10-4 fraction 2: 1) to obtain three fractions (CUB-10-4-1 ~ CUB-10-4-3), the compound represented by the following formula (1) (CUB-10-4-2, 10mg ) Was separated.

[Formula 1]

Comparative Example 1

Turmeric, ethyl acetate and water fractions obtained in Example 1 were carried out in the same manner as in Example 1 to separate and purify each fraction. As a result, the compound represented by Formula 1 was not detected.

Experimental Example 1

First, in order to confirm the hepatocellular protective activity against hepatotoxicity induced by acetaminophen using a human liver cancer cell line (HepG2 cell), 10% (v / v) fetal bovine serum (HepG2 cell) was used. FBS), penicillin (cultured in 100 U / mL), streptomycin (100 ㎍ / mL) was added to a DMEM medium at a temperature of 37 ℃ a 5% CO ₂ cell incubator maintained.

After culturing the human liver cancer cell line at a concentration of 2 × 10 ⁵ cells / ml for 24 hours, the compound represented by Formula 1 according to Example 1 was treated with hepatocytes at a concentration of 10 μM for 2 hours, and then 10 mM acetaminophen. Cell viability was measured after induction of hepatotoxicity for 24 hours.

At this time, hepatic cancer cell line treated with acetaminophen was not treated as a control group, and hepatic cancer cell line treated with only acetaminophen as a negative control group was used as a control. Liver cancer cell lines treated with acetaminophen after 2 hours pretreatment at 20 μM, 50 μM and 100 μM concentrations were used. On the other hand, MTT assay was used to measure cell viability, and the reaction was completed for 1 hour after treatment with Thiazolyl blue tetrazolium bromide (MTT) reagent at a final concentration of 1 mg / ml. After cell culture was removed, the absorbance was measured at 540 nm using a microplate reader (Synergy H1, BioTek) after dissolving formazan formed by DMSO. The cell viability was measured by the absorbance of the sample treated group compared to the normal control group without treatment. It is expressed as a percentage of the ratio, and the results are shown in FIG. 1.

As can be seen through Figure 1, the compound represented by Formula 1 (Sample 1) has the effect of improving the cell survival rate of human liver cancer cell line (HepG2) by inhibiting liver toxicity induced by acetaminophen treatment, in particular a positive control group It can be seen that even if treated at a lower concentration than in silymarin, hepatocellular protective effect is more excellent.

Experimental Example 2

The experiment was carried out in the same manner as in Experiment 1, but the AST activity level was evaluated, not the cell viability. Specifically, the AST activity was measured at 450 nm using an Aspartate Aminotransferase (AST) activity assay kit (Sigma). After quantified by the following AST activity calculation method, the results are shown in Figure 2 below.

* B = amount of glutamate produced (nmole)

As can be seen from FIG. 2, the compound represented by Chemical Formula 1 (Sample 1) is significantly lowered through the treatment of the compound represented by Chemical Formula 1 or the compound represented by Chemical Formula 1, or the AST activity level increased by acetaminophen treatment. You can check it. In addition, it can be seen that more effective in reducing the AST activity level than silymarin treated at a higher concentration.

Experimental Example 3

The experiment was performed in the same manner as in Experimental Example 1, but the change in LDH concentration was measured, not the cell viability. That is, when hepatocytes are killed by injury, LDH (Lactate dehydrogenase) enzymes present in hepatocytes are released from the cells and the concentration is increased. Therefore, if the LDH concentration can be reduced, it can be regarded as an inhibitory effect on hepatocyte death.

Specifically, the LDH activity was measured at 490 nm using the LDH Cytotoxicity Detection Kit (TAKARA) and expressed as a percentage of the absorbance ratio of the sample treated group compared to the normal control group which did not process the sample. 3 is shown.

As can be seen through Figure 3, it can be seen that the increased LDH concentration by acetaminophen treatment is significantly reduced through the treatment of the compound represented by Formula 1 (Sample 1), through which the hepatocytes damaged by the drug It can be seen that the killing effect. In addition, it can be seen that more effective in reducing the LDH concentration than the higher concentration of silymarin treated.

 Preparation Example 1-Medicine

<Manufacture Example 1-1>-powder

50 mg of the compound represented by Chemical Formula 1 of Example 1 and 2 g of crystalline cellulose were mixed and filled into an airtight cloth according to a conventional powder preparation method to prepare a powder.

Preparation Example 1-2

50 mg of the compound represented by Chemical Formula 1 of Example 1, 400 mg of crystalline cellulose, 5 mg of magnesium stearate were mixed, and then compressed into tablets according to a conventional tablet preparation method.

<Manufacture Example 1-3>-Capsule

30 mg of the compound represented by Formula 1 of Example 1, 100 mg of whey protein, 400 mg of crystalline cellulose, 6 mg of magnesium stearate were mixed, and then filled into gelatin capsules according to a conventional capsule preparation method to prepare a capsule.

[Production Example 2]-Food

Preparation Example 2-1 Preparation of Health Foods

1000 mg of the compound represented by Formula 1 of Example 1, 70 μg of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.5 μg of vitamin B6, 0.2 μg of vitamin B12, vitamin C 10 mg, biotin 10 μg, nicotinic acid amide 1.7 mg, folic acid 50 ug, calcium pantothenate 0.5 mg, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium monophosphate 15 mg, dicalcium phosphate 55 mg, potassium citrate It can be prepared by mixing 90 mg, calcium carbonate 100 mg, magnesium chloride 24.8 mg, may be optionally modified the mixing ratio, after mixing the above components in accordance with the usual health food manufacturing method, and then preparing granules. It was.

Preparation Example 2-2 Preparation of Healthy Drinks

Purified water was added to 1000 mg of the compound represented by Formula 1 of Formula 1, 1000 mg of citric acid, 100 g of oligosaccharide, 2 g of plum concentrate, and 1 g of taurine, and the above ingredients were mixed according to a total 900 ml conventional health beverage preparation method. Then, after stirring and heating at 85 ℃ for about 1 hour, the resulting solution was filtered and obtained in a sterilized 2L container, sealed sterilized and then refrigerated and stored as a healthy beverage.

Although one embodiment of the present invention has been described above, the spirit of the present invention is not limited to the embodiments set forth herein, and those skilled in the art who understand the spirit of the present invention may add components within the scope of the same idea. Other embodiments may be easily proposed by changing, deleting, adding, etc., but this is also within the scope of the present invention.

Claims (9)

delete delete delete delete A pharmaceutical composition for preventing and treating liver damage comprising a compound represented by the following Formula 1 or a salt thereof as an active ingredient.
[Formula 1]

The method of claim 5,
Compound represented by the formula (1 ) is liver pharmaceutical composition for preventing and treating liver damage, characterized in that derived from (Cu rcuma longa) . delete Food composition for preventing and improving liver damage comprising a compound represented by the formula (1) or a salt thereof as an active ingredient.
[Formula 1]

The method of claim 8,
The compound represented by the formula (1 ) is liver food (Cu rcuma longa) characterized in that derived from liver damage prevention and improvement food composition.

Images